Oblato, Inc. announced that it will issue 15,000,000 common shares at an issue price for gross proceeds of KRW 18,408,000,000 on February 6, 2023. The transaction will include participation from HLB Therapeutics Co.,Ltd. The transaction has been approved by the board of directors of the company. The company is expected to close the transaction on February 14, 2023.